Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
AVDL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.70
vs -0.50
Q3.23
N/A
-0.41
vs -0.33
Q4.23
N/A
-0.32
vs -0.44
Q1.24
N/A
-0.30
vs -0.48
Q2.24
N/A
-0.14
vs -0.70
Q3.24
N/A
-0.03
vs -0.41
Q4.24
N/A
-0.05
vs -0.32
Q1.25
N/A
-0.05
vs -0.30
Q2.25
+126%
0.04
vs -0.14
Q3.25
+460%
0.11
vs -0.03
Sales Growth
YoY
Current
Estimates
Q2.23
NA
1.5M vs NA
Q3.23
NA
7M vs NA
Q4.23
NA
19.5M vs NA
Q1.24
NA
27.2M vs NA
Q2.24
+2674%
41.5M vs 1.5M
Q3.24
+613%
50M vs 7M
Q4.24
+159%
50.4M vs 19.5M
Q1.25
+93%
52.5M vs 27.2M
Q2.25
+48%
61.5M vs 41.5M
Q3.25
+41%
70.6M vs 50M
Return on Equity
QoQ
Q2.23
-45%
-0.45
vs 0.81
Q3.23
-33%
-0.33
vs -0.45
Q4.23
-33%
-0.33
vs -0.33
Q1.24
-35%
-0.35
vs -0.33
Q2.24
-20%
-0.20
vs -0.35
Q3.24
-4%
-0.04
vs -0.20
Q4.24
-7%
-0.07
vs -0.04
Q1.25
-7%
-0.07
vs -0.07
Institutionnal Ownership
QoQ
Q2.23
111
111
vs 100
11%
Q3.23
109
109
vs 111
-2%
Q4.23
122
122
vs 109
12%
Q1.24
132
132
vs 122
8%
Q2.24
170
170
vs 132
29%
Q3.24
198
198
vs 170
16%
Q4.24
175
175
vs 198
-12%
Q1.25
185
185
vs 175
6%
Quote Panel
Key Metrics
zacks.com
13 hours ago
globenewswire.com
16 hours ago
Forecast
546%2026-Revenue
1650%2026-EPS
-376%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Rodman & Renshaw
initialisePrevious: Not converted
2024-06-11
Now: Buy
Jefferies
downgradePrevious: Not converted
2022-08-09
Now: Buy
Relative Strength
AVDL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
NASDAQ
Unprofitable
Unprofitable
-0.07Â ( -0.73%)
Pre-market 9.60$0.10 (1.05%)
Relative Strenght
61
Volume Buzz
20%
Earning Acce
No
Dist 52w H.
45%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How AVDL compares to sector?
